Cargando…
Giant cell myocarditis following COVID‐19 successfully treated by immunosuppressive therapy
It has been shown that severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), by coronavirus disease 2019 (COVID‐19), can lead to multi‐organ impairment including cardiac involvement and immunological problems. Acute myocarditis is one of serious and fatal complications of COVID‐19. In this c...
Autores principales: | Amiri, Afsaneh, Houshmand, Golnaz, Taghavi, Sepideh, Kamali, Monireh, Faraji, Mona, Naderi, Nasim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361461/ https://www.ncbi.nlm.nih.gov/pubmed/35957785 http://dx.doi.org/10.1002/ccr3.6196 |
Ejemplares similares
-
Targeted treatment in viral‐associated inflammatory cardiomyopathy
por: Amin, Ahmad, et al.
Publicado: (2021) -
Takotsubo syndrome without major stress mimicking myocarditis
por: Taghavi, Sepideh, et al.
Publicado: (2020) -
Combination Immunosuppressive Therapy for Giant Cell Myocarditis
por: Funaki, Takashi, et al.
Publicado: (2022) -
Successful Triple Combination Immunosuppressive Therapy with Prednisolone, Cyclosporine, and Mycophenolate Mofetil to Treat Recurrent Giant Cell Myocarditis
por: Akita, Tomomi, et al.
Publicado: (2019) -
Clinical and Histological Response to Immunosuppressive Therapy in Giant Cell Myocarditis
por: Choi, You-Jung, et al.
Publicado: (2018)